Creative Biolabs highlights how standardized linker–payload sets are helping reduce synthetic complexity and accelerate early ...

CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload ...

Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) ...

Lead author Patricia LoRusso, DO, PhD (hc), FAACR will present an updated data cut from the late breaking abstract on Tuesday, April 21, 2026 at 2:30 – 4:30 pm Pacific Standard Time (PST). The ...

Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, ...

CrossBride Bio is developing a dual-payload cancer drug expected to begin human trials in 2026. ・The U.S. Food and Drug Administration investigational New Drug application for CBB-120 is expected in ...

BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates early clinical activity and favorable safety profile in Phase 1 study as a monotherapy and in ...

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), entered into a licensing agreement with Qurient, a ...

Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced ...

OBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing ...

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a ...